Chief Medical Officer of LimFlow, Inari Medical
Search every verified Shon M.p.h. interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Shon Chakrabarti, an interventional cardiologist by training, serves as Vice President of Medical Affairs and General Manager of Chronic Venous Therapies at Inari Medical. In a September 2023 podcast appearance, he discussed his transition from clinical practice to medical device leadership, describing the shift as requiring a willingness to "get comfortable with discomfort." He stated that his role involves shifting treatment for venous thromboembolism from systemic medical therapy to a device-based removal approach, which he said could have significant benefits for patients. Chakrabarti also reflected on his experience at Abiomed, where he said the company developed a non-permanent temporary implantable pump to bridge patients in cardiogenic shock to heart recovery. He emphasized that medical device technology should address an unmet need and aim to change treatment paradigms, not just add a tool to a toolbox. He advised physicians considering a path to industry leadership to reflect on their goals, stay open-minded, and be prepared for a new training journey that requires full commitment.
“Medical device technology really keys in on the idea of creating a technology that addresses an unmet need, aiming not just to add a widget to a toolbox but to change treatment paradigms completely.”
“At Abiomed, we developed a non-permanent temporary implantable pump to bridge patients in cardiogenic shock to heart recovery, moving away from permanent full support or transplant options.”
“At Inari Medical, we are shifting treatment for venous thromboembolism from systemic medical therapy like anticoagulants to a simple device-based removal approach, which could have significant short and long-term benefits for patients.”
“Physicians adopt new device technologies when there is a big unmet need, tangible visible evidence of impact, and strong supporting data demonstrating improved patient outcomes.”
Unlike previous episodes, our guest also works outside of rare disease and targets a wider population of patients with unmet ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Shon M.p.h..